FOLH1 and neuroendocrine neoplasm: This metabolic shift provides a mechanistic rationale for integrating ^18F-FDG PET in the diagnostic workflow for PSMA-low or neuroendocrine tumors, complementing ^68Ga-PSMA PET [79].